Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

CMS Releases List of 27 Drugs to be Hit With IRA-Related Fines in 2025

  • Post author:PacConAdmin
  • Post published:March 14, 2023
  • Post category:Drug Industry Daily

On Wednesday, the Biden administration released a list of 27 drugs and biologics whose prices are rising faster than the rate of the inflation, and thus whose manufacturers will owe…

Continue ReadingCMS Releases List of 27 Drugs to be Hit With IRA-Related Fines in 2025

FDA Offers Advice on NDAs for Postoperative Local Anesthetics

  • Post author:PacConAdmin
  • Post published:March 14, 2023
  • Post category:Drug Industry Daily

Sponsors developing long-acting local postoperative anesthetics should consider including novel, clinically meaningful endpoints in their trial design, the FDA has said in new draft guidance. Source: Drug Industry Daily

Continue ReadingFDA Offers Advice on NDAs for Postoperative Local Anesthetics

FDA Shares Latest Thinking on Electronic Systems, Signatures and Records in Trials

  • Post author:PacConAdmin
  • Post published:March 14, 2023
  • Post category:Drug Industry Daily

The FDA offers recommendations for using electronic systems, records and signatures in clinical trials, including advice on validation, in a draft guidance released Wednesday. Source: Drug Industry Daily

Continue ReadingFDA Shares Latest Thinking on Electronic Systems, Signatures and Records in Trials

Arkansas Drug Facility Hit for Control and Quality Lapses

  • Post author:PacConAdmin
  • Post published:March 14, 2023
  • Post category:Drug Industry Daily

The FDA dinged Dunagin Pharmaceuticals’ Rogers, Ark., drug manufacturing facility for its water system, its drug manufacturing and equipment cleaning processes, and for other deficiencies observed during an Aug. 29…

Continue ReadingArkansas Drug Facility Hit for Control and Quality Lapses

Cipla Plant Rapped for Serious Quality and Systems Lapses

  • Post author:PacConAdmin
  • Post published:March 6, 2023
  • Post category:Drug Industry Daily

The FDA dinged generics maker Cipla’s quality unit for several lapses, including failing to properly investigate batch discrepancies or the impact of power outages on drug product, during a Feb.…

Continue ReadingCipla Plant Rapped for Serious Quality and Systems Lapses

B. Braun Gets Form 483 for Batch Discrepancies, Quality Lapses

  • Post author:PacConAdmin
  • Post published:March 6, 2023
  • Post category:Drug Industry Daily

The FDA rapped German pharmaceutical company B. Braun Medical for failing to thoroughly review unexplained batch discrepancies, a quality control unit that lacks the authority over drug products, failure to…

Continue ReadingB. Braun Gets Form 483 for Batch Discrepancies, Quality Lapses

FDA and FTC Team Up to Counter Misleading Info About Biosimilars

  • Post author:PacConAdmin
  • Post published:March 6, 2023
  • Post category:Drug Industry Daily

The FDA and the Federal Trade Commission (FTC) have launched a campaign against false or misleading information about biosimilars that “may constitute unfair or deceptive practices” leading to decreased confidence…

Continue ReadingFDA and FTC Team Up to Counter Misleading Info About Biosimilars

Genentech Seeks Patent Royalties From Biogen for Blockbuster MS Drug

  • Post author:PacConAdmin
  • Post published:March 6, 2023
  • Post category:Drug Industry Daily

Genentech has filed a complaint against Biogen seeking patent royalties from a manufacturing process Biogen allegedly used to produce its multiple sclerosis (MS) drug Tysabri (natalizumab). Source: Drug Industry Daily

Continue ReadingGenentech Seeks Patent Royalties From Biogen for Blockbuster MS Drug

Many Accelerated Approval Drug Labels Lack Required Marketing Information

  • Post author:PacConAdmin
  • Post published:March 6, 2023
  • Post category:Drug Industry Daily

More than 10 percent of drugs marketed with an Accelerated Approval (AA) failed to include mention of the AA on the label, a new study has found. Source: Drug Industry…

Continue ReadingMany Accelerated Approval Drug Labels Lack Required Marketing Information

As DSCSA Deadline Looms, Manufacturers’ Supply Chains Still Have Far to Go

  • Post author:PacConAdmin
  • Post published:March 5, 2023
  • Post category:Drug Industry Daily

Drugmakers and others in the pharmaceutical supply chain still have much overhauling of shipping and verification systems and processes to do if they are to meet the Nov. 27 deadline…

Continue ReadingAs DSCSA Deadline Looms, Manufacturers’ Supply Chains Still Have Far to Go
  • Go to the previous page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.